Richard Sullivan is Professor, Cancer & Global Health at Kings College London (KCL) and founding director of the Institute of Cancer Policy. Richard is an executive member of the King’s Health Partners Comprehensive Cancer Centre and board member of the Union for International Cancer Control (UICC). He holds Visiting Chairs at the Universidad Catolica, Santiago and Tata Memorial Centre. Richard also serves on the board of the Centre for Global Health at King’s, and is Co-Director of the King’s Conflict & Health Research Group.
Richard is past UK Director of the Council for Emerging National Security Affairs (CENSA) a national security think-tank where he specialised in counter-proliferation and the security implications of global health. Richard qualified in medicine, and trained in academic surgery (urology) gaining his PhD in fundamental aspects of cell signalling from University College London. He was also clinical director of Cancer Research UK between 1999 and 2008. Following a period at the London School of Economics working on complex healthcare systems within the health, society and population programme he moved to KCL in 2011. Richard’s research programmes at KHP CCC focus on to areas: global cancer policy and conflict & health. In global cancer public policy the ICP have worked on a number of Commissions such as the Lancet Oncology Delivering affordable cancer care in high-income countries, the Global childhood cancer series, Health and cancer in India series and, most recently, Lancet commission on Global Surgery 2030, and the Lancet series on women’s equity, health and cancer.
Conflict & Research Group is also carrying out a Lancet Commission into civil-military co-operation in global health, in addition to a wide variety of field studies including: Basic package of health services in Afghanistan, armed violence reduction as public health measure, intelligence, security and global health, health intelligence in the Syrian conflict and military-civil technology flows in health. Richard has worked extensively in many conflict regions from the Balkans through to Afghanistan, Libya, Syria and DR Congo in both healthcare systems reconstruction and cancer control.